

Резюме: Шилова Ольга Николаевна

Адрес

Федеральное государственное бюджетное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук, Москва, Россия

Контакты

<https://www.ibch.ru/users/1254>

Образование

2015–2019	Россия, Москва	Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук
2010–2015	Россия, Москва	Московский государственный университет имени М.В.Ломоносова, Биологический факультет

Работа в ИБХ

2020–наст.вр.	Научный сотрудник
---------------	-------------------

Научные интересы

Таргетная терапия оухолей, рекомбинантные белки для тераностики, направляющие модули неиммуноглобулиновой природы

Степени и звания

Кандидат наук (Биологические науки, 03.00.03 — Молекулярная биология)

Гранты и проекты

2019–2023	Разработка адресной системы на основе анти-HER2-скаффолдов и молекулярной пары барназа-барстар для ступенчатой доставки цитотоксинов при терапии HER2-положительных злокачественных новообразований.
2017–2021	Новые подходы к адресной терапии злокачественных новообразований с использованием инновационного направляющего модуля неиммуноглобулиновой природы

Публикации

1. Shipunova VO, Belova MM, Kotelnikova PA, **Shilova ON**, Mirkasymov AB, Danilova NV, Komedchikova EN, Popovtzer R, Deyev SM, Nikitin MP (2022). Photothermal Therapy with HER2-Targeted Silver Nanoparticles Leading to Cancer Remission. *Pharmaceutics* 14 (5), , [10.3390/pharmaceutics14051013](#)
2. **Shilova ON**, Tsyba DL, Shilov ES (2022). Mutagenic Activity of AID/APOBEC Deaminases in Antiviral Defense and Carcinogenesis. *Mol Biol* 56 (1), 46–58, [10.1134/S002689332201006X](#)
3. **Shilova ON**, Tsyba DL, Shilov ES (2022). [Mutagenic Activity of AID/APOBEC Deaminases in Antiviral Defense and Carcinogenesis]. *Mol Biol (Mosk)* 56 (1), 55–68, [10.31857/S0026898422010086](#)
4. Shipunova VO, Kovalenko VL, Kotelnikova PA, Sogomonyan AS, **Shilova ON**, Komedchikova EN, Zvyagin AV, Nikitin MP, Deyev SM (2022). Targeting cancer cell tight junctions enhances plga-based photothermal sensitizers' performance in vitro and in vivo. *Pharmaceutics* 14 (1), , [10.3390/pharmaceutics14010043](#)
5. **Shilova O**, Kotelnikova P, Proshkina G, Shramova E, Deyev S (2021). Barnase-barstar pair: Contemporary application in cancer research and nanotechnology. *Molecules* 26 (22), , [10.3390/molecules26226785](#)
6. **Shilova O**, Shramova E, Proshkina G, Deyev S (2021). Natural and Designed Toxins for Precise Therapy:

- Modern Approaches in Experimental Oncology. *Int J Mol Sci* 22 (9), , [10.3390/ijms22094975](https://doi.org/10.3390/ijms22094975)
7. **Shilova ON**, Deyev SM (2019). DARPin: Promising Scaffolds for Theranostics. *Acta Naturae* 11 (4), 42–53, [10.32607/20758251-2019-11-4-42-53](https://doi.org/10.32607/20758251-2019-11-4-42-53)
 8. Sokolova EA, **Shilova ON**, Kiseleva DV, Schulga AA, Balalaeva IV, Deyev SM (2019). HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model. *Int J Mol Sci* 20 (10), , [10.3390/ijms20102399](https://doi.org/10.3390/ijms20102399)
 9. Kuzichkina EO, **Shilova ON**, Deyev SM (2018). The Mechanism of Fluorescence Quenching of Protein Photosensitizers Based on miniSOG During Internalization of the HER2 Receptor. *Acta Naturae* 10 (4), 87–94, [10.32607/20758251-2018-10-4-87-94](https://doi.org/10.32607/20758251-2018-10-4-87-94)
 10. Kuzichkina EO, **Shilova ON**, Deyev SM, Petrov RV (2018). The Application of Recombinant Phototoxins 4D5scFv-miniSOG and DARPin-miniSOG to Study the HER2 Receptor Internalization. *Dokl Biochem Biophys* 482 (1), 245–248, [10.1134/S1607672918050046](https://doi.org/10.1134/S1607672918050046)
 11. Proshkina GM, Shramova EI, **Shilova ON**, Ryabova AV, Deyev SM (2018). Phototoxicity of flavoprotein miniSOG induced by bioluminescence resonance energy transfer in genetically encoded system NanoLuc-miniSOG is comparable with its LED-excited phototoxicity. *J Photochem Photobiol B* 188, 107–115, [10.1016/j.jphotobiol.2018.09.006](https://doi.org/10.1016/j.jphotobiol.2018.09.006)
 12. **Shilova ON**, Shilov ES, Lieber A, Deyev SM (2018). Disassembling a cancer puzzle: Cell junctions and plasma membrane as targets for anticancer therapy. *J Control Release* 286, 125–136, [10.1016/j.jconrel.2018.07.030](https://doi.org/10.1016/j.jconrel.2018.07.030)
 13. Shipunova VO, **Shilova ON**, Shramova EI, Deyev SM, Proshkina GM (2018). A Highly Specific Substrate for NanoLUC Luciferase Furimazine Is Toxic in vitro and in vivo. *Russ. J. Bioorganic Chem.* 44 (2), 225–228, [10.1134/S1068162018020085](https://doi.org/10.1134/S1068162018020085)
 14. Proshkina GM, Kiseleva DV, **Shilova ON**, Ryabova AV, Shramova EI, Stremovskiy OA, Deyev SM (2017). Bifunctional Toxin DARPin-LoPE Based on the Her2-Specific Innovative Module of a Non-Immunoglobulin Scaffold as a Promising Agent for Theranostics. *Mol Biol* 51 (6), 865–873, [10.1134/S0026893317060140](https://doi.org/10.1134/S0026893317060140)
 15. Proshkina GM, Kiseleva DV, **Shilova ON**, Ryabova AV, Shramova EI, Stremovskiy OA, Deyev SM (2017). Bifunctional Toxin DARPin-LoPE Based on the HER2-Specific Innovative Module of a Non-Immunoglobulin Scaffold as a Promising Agent for Theranostics. *Mol Biol (Mosk)* 51 (6), 997–1007, [10.7868/S0026898417060118](https://doi.org/10.7868/S0026898417060118)
 16. **Shilova ON**, Shilov ES, Deyev SM (2017). The effect of trypan blue treatment on autofluorescence of fixed cells. *Cytometry A* 91 (9), 917–925, [10.1002/cyto.a.23199](https://doi.org/10.1002/cyto.a.23199)
 17. **Shilova ON**, Proshkina GM, Ryabova AV, Deyev SM, Petrov RV (2017). Cytotoxicity of targeted HER2-specific phototoxins based on flavoprotein miniSOG is determined by the rate of their internalization. *Dokl Biochem Biophys* 475 (1), 256–258, [10.1134/S1607672917040044](https://doi.org/10.1134/S1607672917040044)
 18. **Shilova ON**, Souslova EA, Pilunov AM, Deyev SM, Petrov RV (2016). Development and investigation of recombinant immunotoxin protein 4D5scFv-mCherry-PE(40). *Dokl Biochem Biophys* 471 (1), 450–453, [10.1134/S160767291606020X](https://doi.org/10.1134/S160767291606020X)
 19. Sokolova E, Proshkina G, Kutova O, **Shilova O**, Ryabova A, Schulga A, Stremovskiy O, Zdobnova T, Balalaeva I, Deyev S (2016). Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo. *J Control Release* 233, 48–56, [10.1016/j.jconrel.2016.05.020](https://doi.org/10.1016/j.jconrel.2016.05.020)
 20. **Shilova ON**, Proshkina GM, Ryabova AV, Deyev SM (2016). Anti-HER2 phototoxin based on flavoprotein miniSOG causes the oxidative stress and necrosis of HER2-positive cancer cells. *Moscow Univ Biol Sci Bull* 71 (1), 14–18, [10.3103/S0096392516010107](https://doi.org/10.3103/S0096392516010107)
 21. Proshkina GM, **Shilova ON**, Ryabova AV, Stremovskiy OA, Deyev SM (2015). A new anticancer toxin based on HER2/neu-specific DARPin and photoactive flavoprotein miniSOG. *Biochimie* 118, 116–122, [10.1016/j.biochi.2015.08.013](https://doi.org/10.1016/j.biochi.2015.08.013)
 22. **Shilova ON**, Proshkina GM, Lebedenko EN, Deyev SM (2015). Internalization and Recycling of the HER2 Receptor on Human Breast Adenocarcinoma Cells Treated with Targeted Phototoxic Protein DARPinminiSOG. *Acta Naturae* 7 (3), 126–32.
 23. **Shilova ON**, Proshkina GM, Lebedenko EN, Deyev SM (2015). Internalization and Recycling of the HER2 Receptor on Human Breast Adenocarcinoma Cells Treated with Targeted Phototoxic Protein

